3SBio received permission from the SFDA to conduct the China arm of the multi-national Phase III trial of voclosporin, a new generation calcineurin inhibitor. 3SBio in-licensed the drug from Isotechnika Pharma of Canada in 2010. The drug suppresses immune system activity and will be tested in patients undergoing renal transplants. More details... Stock Symbols: (NSDQ: SSRX) (TSX: ISA) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});